Skip to main content
. 2018 Jul 16;9(16):2765–2772. doi: 10.7150/jca.23456

Figure 1.

Figure 1

Overall survival (OS) curves for the CF-RT (cisplatin, 5-fluorouracil and radiotherapy) and DCF-RT (docetaxel, cisplatin, 5-fluorouracil and radiotherapy) groups. OS rates at 2 and 3 years are 45.0% and 37.5%, respectively, in the CF-RT group and 62.9% and 56.7%, respectively, in the DCF-RT group, with a significant intergroup difference (p = 0.032).